Farallon Capital Management’s Gossamer Bio GOSS Stock Holding History

Farallon Capital Management’s Portfolio GOSS Stock Details GOSS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-76,628	Closed	-$7.23M	–	177
2024 Q1	$7.23M	Hold	76,628	–	–	0.03%	97
2023 Q4	$5.59M	Hold	76,628	–	–	0.03%	89
2023 Q3	$5.11M	Buy	+76,628	New	+$7.06M	0.02%	98
2021 Q3	–	Sell	-2,529	Closed	-$1.64M	–	304
2021 Q2	$1.64M	Buy	+2,529	New	+$1.75M	0.01%	213
2020 Q3	–	Sell	-1,250	Closed	-$1.3M	–	128
2020 Q2	$1.3M	Hold	1,250	–	–	0.01%	117
2020 Q1	$1.02M	Sell	1,250 -5,000	-80%	-$5.22M	0.01%	98
2019 Q4	$7.82M	Buy	6,250 +4,991	+396%	+$8.04M	0.05%	103
2019 Q3	$1.69M	Buy	1,259 +9	+0.7%	+$14.3K	0.01%	96
2019 Q2	$2.22M	Sell	1,250 -3,473	-74%	-$5.32M	0.01%	99
2019 Q1	$8.19M	Buy	+4,723	New	+$7.88M	0.06%	85

Other funds holding GOSS

NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return

Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Octagon Capital Advisors New York $1.11B AUM 866.76% 1-Year Est. Return

Arch Venture Management Chicago, Illinois $1.1B AUM 356.62% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return

Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return

6CM

683 Capital Management New York $2.04B AUM 94.26% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Farallon Capital Management's GOSS Position: Q2 2024 in Review

Farallon Capital Management sold out of Gossamer Bio (GOSS) in Q2 2024, closing a stake of 76,628 shares — an estimated $7.23M sold.

Farallon Capital Management first reported a position in GOSS in Q1 2019 and held it in 10 quarters. The position peaked at $8.19M in Q1 2019. 93 funds tracked by Wall St. Rank hold GOSS as of Q2 2024.

Farallon Capital Management reported no remaining Gossamer Bio position as of Q2 2024 after selling out during the quarter.
Farallon Capital Management sold 76,628 Gossamer Bio shares in Q2 2024, an estimated $7.23M.
Farallon Capital Management first reported a position in Gossamer Bio in Q1 2019 and held it in 10 quarters.
Farallon Capital Management's Gossamer Bio position peaked at $8.19M in Q1 2019.
93 funds tracked by Wall St. Rank held Gossamer Bio as of Q2 2024.

Based on Farallon Capital Management's 13F filing for Q2 2024, filed 14 Aug 2024.